Effectiveness and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Safety and Effectiveness of Adalimumab in Patients Diagnosed With Rheumatoid Arthritis

NCT01078571 ·Status: COMPLETED

Post-marketing Observational Study in Subjects With Rheumatoid Arthritis

NCT00234884 ·Status: COMPLETED

Safety and Effectiveness and Effect on Quality of Life and Work Productivity of Humira in Patients With Psoriatic Arthritis in Clinical Routine

NCT01078610 ·Status: WITHDRAWN

A Study in Rheumatoid Arthritis (RA) Patients to Compare Two Formulations of Adalimumab for Pharmacokinetic, Pharmacodynamic and Safety

NCT01712178 ·Status: COMPLETED ·Phase: PHASE2

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

NCT01117480 ·Status: COMPLETED

A Study of Adalimumab When Added to Inadequate Standard Anti-rheumatic Therapy in Patients With Active Rheumatoid Arthritis

NCT01231321 ·Status: COMPLETED ·Phase: PHASE3

Crossover Study of Safety and Tolerability of Two Formulations of Adalimumab.

NCT01561313 ·Status: COMPLETED ·Phase: PHASE2

Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-390 With Adalimumab

NCT01752855 ·Status: COMPLETED ·Phase: PHASE2

Efficacy and Safety of Adalimumab in Patients With Active Rheumatoid Arthritis Treated Concomitantly With Methotrexate.

NCT00195702 ·Status: COMPLETED ·Phase: PHASE3

A Crossover Study of the Safety and Tolerability of Two Formulations of Adalimumab

NCT01502423 ·Status: COMPLETED ·Phase: PHASE2

Assessment of Clinical Effectiveness and Safety of Adalimumab and High Dose Methotrexate in Routine Clinical Practice

NCT01736189 ·Status: COMPLETED

Assessment of the Safety of Adalimumab in Rheumatoid Arthritis Patients Showing Rapid Progression of Structural Damage of the Joints, Who Have no Prior History of Treatment With Disease-modifying Anti-rheumatic Drugs or Biological Agents

NCT01783730 ·Status: COMPLETED

Study to Characterize Demographics, Compliance, Tolerability and Safety in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Prescribed Adalimumab (Humira®) as Part of Routine Clinical Care

NCT01163916 ·Status: COMPLETED

Assessment of Pain Management in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Patients Who Are About to be Treated With Adalimumab

NCT01273519 ·Status: COMPLETED

Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis

NCT01474876 ·Status: COMPLETED

A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate

NCT04909801 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Early Access Program of the Safety of Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Rheumatoid Arthritis

NCT00650026 ·Status: APPROVED_FOR_MARKETING

Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy

NCT00646178 ·Status: COMPLETED ·Phase: PHASE3

Study of the Human Anti-TNF Monoclonal Antibody in Patients With Active Rheumatoid Arthritis

NCT00649545 ·Status: APPROVED_FOR_MARKETING

Efficacy of HUMIRA in Subjects With Active Rheumatoid Arthritis

NCT00234897 ·Status: COMPLETED ·Phase: PHASE4

A Pilot Study of the Feasibility of Discontinuation of Adalimumab in Stable Rheumatoid Arthritis Patients in Clinical Remission

NCT00808509 ·Status: COMPLETED ·Phase: PHASE4

A 3-year Study Following up Patients With Moderate to Severe Rheumatoid Arthritis Treated With Humira in Greece

NCT01086033 ·Status: COMPLETED

Open Label Study to Assess Efficacy and Safety of the Fully Human Anti-TNF-Alpha Monoclonal Antibody Adalimumab

NCT00650390 ·Status: APPROVED_FOR_MARKETING

A Study of Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis

NCT00647491 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Study Comparing 80 mg of Adalimumab With Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week Dosing

NCT00647270 ·Status: COMPLETED ·Phase: PHASE3